Quantcast

Industry news that matters to you.  Learn more

Archives for February 2017

Invivoscribe Expands Ion PGM NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today released three additional CE-marked next-generation sequencing (NGS) assay kits for in vitro diagnostic (IVD) use to assist in the diagnosis of B-cell malignancies. Invivoscribe has now commercialized more than 40 CE-IVD assays and bioinformatics packages for capillary electrophoresis and NGS platforms and has recently announced a long-term agreement with Thermo Fisher Scientific to bring regulated IVD assays through the FDA on the Ion PGM™ Dx System.

Study Finds Biomarker for Lung Cancer Detection in the Nasal Passages of Smokers

A new nasal test may allow patients suspected of having lung cancer to undergo a simple swab of their nose to determine if they have the disease. Researchers at Boston University School of Medicine (BUSM) have found that a genomic biomarker in the nasal passage can accurately determine the likelihood of a lung lesion being malignant. The findings, which appear online in the Journal of the National Cancer Institute, will allow physicians to confidently identify patients who are at low probability for having lung cancer, thus sparing them from costly and risky procedures.

Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker

Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

Blood-based Diagnostic Assay from Biodesix Measures Immunotherapy Biomarker PD-L1

New data from Biodesix® evaluating an assay in development demonstrated the potential to measure circulating PD-L1 through mRNA in blood through multiplexed droplet digital™ PCR (ddPCR, Bio-Rad, Inc.) detection. The assay uses proprietary RNA isolation methods consistent with Biodesix’s commercialized GeneStrat® ALK, ROS1, and RET variant tests. Existing immunohistochemistry (IHC) PD-L1 tissue tests are used to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the ASCO-SITC Clinical Immuno-Oncology Program in Orlando, Florida.

BrainScope Biomarker Adds Significant Prognostic Accuracy for Rapid Assessment of Traumatic Brain Injury

BrainScope Company, Inc. recently announced a publication demonstrating that prediction of a CT positive traumatic brain injury (TBI) is significantly improved when the electroencephalography (EEG) based biomarker from its Ahead 300 is used in addition to the most commonly considered predictive risk factor, Loss of Consciousness (LOC). The results of this study entitled “Increased prognostic accuracy of TBI when a brain electrical activity biomarker is added to Loss of Consciousness (LOC),” were published in the peer-reviewed American Journal of Emergency Medicine. Results of this study show an 83% improvement in the prediction of TBI using the Ahead 300 compared to that obtained using a history of LOC alone or LOC plus traumatic amnesia, the two most commonly used clinical diagnostic indicators for TBI.